BACKGROUND: The relationship between the age at diagnosis and disease course is poorly defined in children with Crohn's disease (CD). We examined the presentation and course of disease in patients 0-5 compared to 6-17 yr of age at diagnosis. METHODS: We analyzed uniform data from 989 consecutive CD patients collected between January 2000 and November 2003, and stored in the Pediatric IBD Consortium Registry. The statistical tests account for the length of follow-up of each patient. RESULTS: In total, 98 patients (9.9%) were of 0-5 yr of age at diagnosis. The mean follow-up time was 5.6 +/- 5.0 yr in the younger group and 3.3 +/- 2.8 yr in the older group (P < 0.001). Race/ethnicity differed by the age group (P= 0.015); a larger proportion of the younger group was Asian/Pacific Islander or Hispanic, and a larger proportion of the older group was African American. The initial classification as ulcerative colitis or indeterminate colitis was more common among the 0-5 yr of age group (P < 0.001). The 6-17 yr of age patients presented with more abdominal pain (P < 0.001), weight loss (P= 0.001), or fever (P= 0.07), while the 0-5 yr of age patients presented with more rectal bleeding (P= 0.008). The 6-17 yr of age patients were more likely to be treated with antibiotics (P < 0.001), 6-mercaptopurine/azathioprine (P < 0.001), infliximab (P= 0.001), or corticosteroids (P= 0.0006). The 6-17 yr of age patients had a higher cumulative incidence of treatment with 5-aminosalicylates (P= 0.009) or methotrexate (P= 0.04). The risk for developing an abscess (P= 0.001), a fistula (P= 0.02), a stricture (P= 0.05), or a perianal fissure (P= 0.06) was greater in the 6-17 yr of age patients. CONCLUSIONS: The 6-17 yr of age patients with CD appear to have a more complicated disease course compared to 0-5 yr of age children. The 0-5 yr of age group may represent a unique disease phenotype and benefit from different approaches to management. Long-term prospective studies are required to validate these findings.
BACKGROUND: The relationship between the age at diagnosis and disease course is poorly defined in children with Crohn's disease (CD). We examined the presentation and course of disease in patients 0-5 compared to 6-17 yr of age at diagnosis. METHODS: We analyzed uniform data from 989 consecutive CDpatients collected between January 2000 and November 2003, and stored in the Pediatric IBD Consortium Registry. The statistical tests account for the length of follow-up of each patient. RESULTS: In total, 98 patients (9.9%) were of 0-5 yr of age at diagnosis. The mean follow-up time was 5.6 +/- 5.0 yr in the younger group and 3.3 +/- 2.8 yr in the older group (P < 0.001). Race/ethnicity differed by the age group (P= 0.015); a larger proportion of the younger group was Asian/Pacific Islander or Hispanic, and a larger proportion of the older group was African American. The initial classification as ulcerative colitis or indeterminate colitis was more common among the 0-5 yr of age group (P < 0.001). The 6-17 yr of age patients presented with more abdominal pain (P < 0.001), weight loss (P= 0.001), or fever (P= 0.07), while the 0-5 yr of age patients presented with more rectal bleeding (P= 0.008). The 6-17 yr of age patients were more likely to be treated with antibiotics (P < 0.001), 6-mercaptopurine/azathioprine (P < 0.001), infliximab (P= 0.001), or corticosteroids (P= 0.0006). The 6-17 yr of age patients had a higher cumulative incidence of treatment with 5-aminosalicylates (P= 0.009) or methotrexate (P= 0.04). The risk for developing an abscess (P= 0.001), a fistula (P= 0.02), a stricture (P= 0.05), or a perianal fissure (P= 0.06) was greater in the 6-17 yr of age patients. CONCLUSIONS: The 6-17 yr of age patients with CD appear to have a more complicated disease course compared to 0-5 yr of age children. The 0-5 yr of age group may represent a unique disease phenotype and benefit from different approaches to management. Long-term prospective studies are required to validate these findings.
Authors: Neera Gupta; Stanley A Cohen; Alan G Bostrom; Barbara S Kirschner; Robert N Baldassano; Harland S Winter; George D Ferry; Terry Smith; Oren Abramson; Benjamin D Gold; Melvin B Heyman Journal: Gastroenterology Date: 2006-04 Impact factor: 22.682
Authors: T Jess; E V Loftus; W S Harmsen; A R Zinsmeister; W J Tremaine; L J Melton; P Munkholm; W J Sandborn Journal: Gut Date: 2006-01-19 Impact factor: 23.059
Authors: Petar Mamula; Grzegorz W Telega; Jonathan E Markowitz; Kurt A Brown; Pierre A Russo; David A Piccoli; Robert N Baldassano Journal: Am J Gastroenterol Date: 2002-08 Impact factor: 10.864
Authors: Neera Gupta; Alan G Bostrom; Barbara S Kirschner; George D Ferry; Harland S Winter; Robert N Baldassano; Benjamin D Gold; Oren Abramson; Terry Smith; Stanley A Cohen; Melvin B Heyman Journal: Pediatrics Date: 2007-12 Impact factor: 7.124
Authors: Michael J Rosen; Rebekah Karns; Jefferson E Vallance; Ramona Bezold; Amanda Waddell; Margaret H Collins; Yael Haberman; Phillip Minar; Robert N Baldassano; Jeffrey S Hyams; Susan S Baker; Richard Kellermayer; Joshua D Noe; Anne M Griffiths; Joel R Rosh; Wallace V Crandall; Melvin B Heyman; David R Mack; Michael D Kappelman; James Markowitz; Dedrick E Moulton; Neal S Leleiko; Thomas D Walters; Subra Kugathasan; Keith T Wilson; Simon P Hogan; Lee A Denson Journal: Gastroenterology Date: 2017-01-26 Impact factor: 22.682
Authors: Tolulope O Falaiye; Keisha R Mitchell; Zengqi Lu; Benjamin R Saville; Sara N Horst; Dedrick E Moulton; David A Schwartz; Keith T Wilson; Michael J Rosen Journal: J Pediatr Gastroenterol Nutr Date: 2014-02 Impact factor: 2.839
Authors: Neera Gupta; Alan G Bostrom; Barbara S Kirschner; George D Ferry; Benjamin D Gold; Stanley A Cohen; Harland S Winter; Robert N Baldassano; Oren Abramson; Terry Smith; Melvin B Heyman Journal: Inflamm Bowel Dis Date: 2010-04 Impact factor: 5.325
Authors: Francesca Maccioni; Franca Viola; Federica Carrozzo; Giovanni Di Nardo; Anna Rosaria Pino; Ilaria Staltari; Najwa Al Ansari; Annarita Vestri; Alberto Signore; Mario Marini; Salvatore Cucchiara Journal: Eur Radiol Date: 2012-08-25 Impact factor: 5.315